Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 1997

View Archived Issues

Company Profile: Supratek Pharma

Bone-targeted carbonic anhydrase inhibitors from RCT

Lilly breaks ground for new Sphinx research facility

Perkin-Elmer and PerSeptive Biosystems to merge

Biologics license issued for Carticel

U.S. patent issued for CEP-2563

Phase II trials of ISIS-3521 begin

PRISM-PLUS results on tirofiban released

TNK-tPA as effective as tPA, studies show

Innothera describes agents for venous function deficiency

Data sheet for Lariam updated

Malignant melanoma indication approved for Intron A in U.K.

New treatment option for cancer pain

BioChem Pharma files first marketing application for lamivudine in hepatitis

S-15535 tested in preclinical models of anxiety and depression

Osteopatch diagnostic system enters clinical trials

Zerit receives E.U. approval

Ergo Science submits NDA for Ergoset

InSite obtains license for retinal drug delivery technology

Antioxidant properties of T-593 contribute to gastroprotection in the rat

Calcium channel antagonist AJ-3941 for treatment of stroke

Cardiovascular and antiarrhythmic activities of HNS-32

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...